Rate of Change of HbA1c (dx/dt) May Predict Progression to Type 2 DM

Stopped early

Conditions studied: Diabetes Mellitus Type 2

In brief

The investigators hypothesize that the HbA1c shows a rising trend in pre-diabetics and normal population with risk factors of developing type 2 DM. There is no known diabetes model for predicting incident diabetes in an individual which takes into account the rate of change of HbA1c (dx/dt). In such cases, the rate of change of HbA1c may give the physicians lead time needed to implement the Diabetes Prevention Program measures.

Key facts

Study ID

NCT01315808

Run by

Wyckoff Heights Medical Center

People needed

542

Starts

2011-03-01

Expected to finish

2012-09-01

Last updated by the study team

2012-03-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• No self-reported history of diabetes or pre-diabetes defined as per ADA criteria
• Age greater than 18 years
• Scheduled to receive HbA1c in participating clinic
• Able and willing to give legally effective consent
• Able and willing to participate in patient questionnaires(attached)

You may not qualify if…

• Previously or currently taking medications for lowering glucose (i.e., exenatide, pramlintide, metformin, rosiglitazone, pioglitazone, or future diabetes drugs) based on self-report and/or prescreening. Patients on drugs causing hyperglycemia like Oral Steroids will be excluded.
• Baseline HbA1c level above 5.7
• Severe Anemia (defined as Hb less than 8gm/dL)
• Patients with hemoglobinopathies
• Pregnancy
• Polycystic ovarian disease

Where it is running

• Wyckoff Heights Medical Center — Brooklyn, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.